Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance ...
Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
Fluticasone propionate 44mcg/inh, 110mcg/inh, 220mcg/inh; metered dose inhaler; CFC-free. Flovent HFA is supplied in the following boxes of 1 as a pressurized aluminum canister fitted with a ...
YARDLEY, PA — The U.S. Food and Drug Administration (FDA) recently approved XHANCE® (fluticasone propionate) nasal spray, developed by Optinose (NASDAQ: OPTN), for the treatment of chronic ...
Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and ...
Objective: To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP) combination product (50/100µg twice daily) with budesonide (BUD) at a four-fold higher microgram ...
Mylan obtained approval to market the generic dubbed Wixela Inhub in three strengths: fluticasone propionate 100 mcg/salmeterol 50 mcg, fluticasone propionate 250 mcg/salmeterol 50 mcg and ...
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Selected from data included with permission and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback